CD274 and neoplasm: Given the fact that anti-VEGF therapy disrupted tumor blood vessels, we evaluated whether the modulation of VEGFR2 signaling in endothelial cells could alter the endothelial cell secretome, thus changing PD-L1 expression on myeloid cells.